Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.eprac.2024.06.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Time to reframe the disease staging system for type 1 diabetes.
Lancet Diabetes Endocrinol
December 2024
Department of Paediatrics, Diabetes Center, University of California San Francisco, San Francisco, California, USA.
Article Synopsis
- A disease staging system introduced in 2015 helps identify and track progression to clinical type 1 diabetes based on islet autoantibodies and dysglycaemia, but it has significant limitations such as combining diverse individuals and lacking high specificity.
- Although the current model suggests a linear progression through stages, real-life progression is often more complex, and factors like age are not considered.
- With the recent FDA approval of teplizumab to delay type 1 diabetes at stage 2, there's a need to refine diabetes staging definitions and develop a risk calculator that considers a wider range of demographic, genetic, and metabolic data, especially in underrepresented groups.
The Role of Teplizumab in Newly Diagnosed Type 1 Diabetes.
Endocr Pract
October 2024
Divsion of Endocrinology, Lipscomb University, Nashville, Tennessee.
Reply to the Letter to the Editor, Endocrine Practice for "Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis".
Endocr Pract
October 2024
Department of Endocrinology, Mymensingh Medical College, Mymensingh 2200, Bangladesh. Electronic address:
Role of Teplizumab, a Humanized Anti-CD3 Monoclonal Antibody, in Managing Newly Diagnosed Type 1 Diabetes: An Updated Systematic Review and Meta-Analysis.
Endocr Pract
May 2024
Department of Endocrinology, CEDAR Superspeciality Healthcare, New Delhi, India.
Objective: Teplizumab has emerged as a potential disease-modifying drug in type 1 diabetes (T1D). This meta-analysis sought to summarize the therapeutic effect of teplizumab in newly diagnosed patients with T1D.
Methods: Randomized controlled trials involving patients with T1D receiving teplizumab in the intervention arm and placebo (or no active intervention) in the control arm were searched throughout the electronic databases.
Approaches to Measuring Beta Cell Reserve and Defining Partial Clinical Remission in Paediatric Type 1 Diabetes.
Children (Basel)
February 2024
Department of Paediatrics and Child Health, University College Cork, T12 DC4A Cork, Ireland.
Context: Type 1 diabetes (T1D) results from the autoimmune T-cell mediated destruction of pancreatic beta cells leading to insufficient insulin secretion. At the time of diagnosis of T1D, there is residual beta cell function that declines over the subsequent months to years. Recent interventions have been approved to preserve beta cell function in evolving T1D.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!